Latest Results From An Ongoing First-In-Human Phase 1A/B Study Of NX-5948, A Selective Bruton’s Tyrosine Kinase (BTK) Degrader, In Patients With Relapsed/Refractory CLL And Other B-Cell Malignancies By dev@sirosolutions.com / December 17, 2024
Targeted Protein Degraders As Next Generation Antibody Payloads By dev@sirosolutions.com / December 11, 2024
The Evolving Chemical Space of Bi-functional Degraders Targeting the CNS By dev@sirosolutions.com / December 11, 2024
